187 related articles for article (PubMed ID: 34910334)
21. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
Nilsson-Ekdahl K; Nilsson B
Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
[TBL] [Abstract][Full Text] [Related]
22. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
[TBL] [Abstract][Full Text] [Related]
23. Role of Escherichia coli K capsular antigens during complement activation, C3 fixation, and opsonization.
Van Dijk WC; Verbrugh HA; van der Tol ME; Peters R; Verhoef J
Infect Immun; 1979 Aug; 25(2):603-9. PubMed ID: 385502
[TBL] [Abstract][Full Text] [Related]
24. A shift of paradigm: From avoiding nanoparticular complement activation in the field of nanomedicines to its exploitation in the context of vaccine development.
Barbey C; Wolf H; Wagner R; Pauly D; Breunig M
Eur J Pharm Biopharm; 2023 Dec; 193():119-128. PubMed ID: 37838145
[TBL] [Abstract][Full Text] [Related]
25. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
26. Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.
La-Beck NM; Islam MR; Markiewski MM
Front Immunol; 2020; 11():603039. PubMed ID: 33488603
[TBL] [Abstract][Full Text] [Related]
27. Reduced erythrocyte CR1 (CD 35) receptor function and complement opsonization in factor I-deficient patients is restored by plasma infusion.
Jepsen HH; Teisner B; Rasmussen JM; Svehag SE
Scand J Immunol; 1989 Feb; 29(2):247-55. PubMed ID: 2522236
[TBL] [Abstract][Full Text] [Related]
28. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci.
Dale JB; Washburn RG; Marques MB; Wessels MR
Infect Immun; 1996 May; 64(5):1495-501. PubMed ID: 8613352
[TBL] [Abstract][Full Text] [Related]
29. Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement.
Verbrugh HA; Peterson PK; Nguyen BY; Sisson SP; Kim Y
J Immunol; 1982 Oct; 129(4):1681-7. PubMed ID: 7108223
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Complement Activation by Nanoparticles.
Neun BW; Ilinskaya AN; Dobrovolskaia MA
Methods Mol Biol; 2018; 1682():149-160. PubMed ID: 29039100
[TBL] [Abstract][Full Text] [Related]
31. The role of poly(ethylene glycol) brush architecture in complement activation on targeted microbubble surfaces.
Chen CC; Borden MA
Biomaterials; 2011 Sep; 32(27):6579-87. PubMed ID: 21683439
[TBL] [Abstract][Full Text] [Related]
32. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide.
Bertholon I; Vauthier C; Labarre D
Pharm Res; 2006 Jun; 23(6):1313-23. PubMed ID: 16715369
[TBL] [Abstract][Full Text] [Related]
33. Complement-Opsonized NIR-IIb Emissive Immunotracers for Dynamically Monitoring Neutrophils in Inflammation-Related Diseases.
Zhang M; Wang Z; Shao Y; Zhao Y; Liu Z
Adv Mater; 2022 Aug; 34(34):e2203477. PubMed ID: 35793262
[TBL] [Abstract][Full Text] [Related]
34. Dichotomy between opsonization and serum complement activation by encapsulated staphylococci.
Peterson PK; Kim Y; Wilkinson BJ; Schmeling D; Michael AF; Quie PG
Infect Immun; 1978 Jun; 20(3):770-5. PubMed ID: 352958
[TBL] [Abstract][Full Text] [Related]
35. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
Blok VT; Daha MR; Tijsma O; Harris CL; Morgan BP; Fleuren GJ; Gorter A
J Immunol; 1998 Apr; 160(7):3437-43. PubMed ID: 9531304
[TBL] [Abstract][Full Text] [Related]
36. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery.
Liu Y; Li K; Liu B; Feng SS
Biomaterials; 2010 Dec; 31(35):9145-55. PubMed ID: 20864169
[TBL] [Abstract][Full Text] [Related]
37. Nanoparticle physicochemical properties determine the activation of intracellular complement.
Ilinskaya AN; Shah A; Enciso AE; Chan KC; Kaczmarczyk JA; Blonder J; Simanek EE; Dobrovolskaia MA
Nanomedicine; 2019 Apr; 17():266-275. PubMed ID: 30794962
[TBL] [Abstract][Full Text] [Related]
38. Targeting nanoparticles to cancer.
Wang M; Thanou M
Pharmacol Res; 2010 Aug; 62(2):90-9. PubMed ID: 20380880
[TBL] [Abstract][Full Text] [Related]
39. The full expression of the ity phenotype in ityr mice requires C3 activation by Salmonella lipopolysaccharide.
Nishikawa F; Yoshikawa S; Harada H; Kita M; Kita E
Immunology; 1998 Dec; 95(4):640-7. PubMed ID: 9893057
[TBL] [Abstract][Full Text] [Related]
40. Opsonization of Legionella pneumophila in human serum: key roles for specific antibodies and the classical complement pathway.
Verbrugh HA; Lee DA; Elliott GR; Keane WF; Hoidal JR; Peterson PK
Immunology; 1985 Apr; 54(4):643-53. PubMed ID: 3980045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
